erlotinib hydrochloride has been researched along with Cancer of Ovary in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Adibkia, K; Aghanejad, A; Barar, J; Mohaghegh, S; Omidi, Y; Tarighatnia, A | 1 |
| Ardighieri, L; Arenare, L; Bagnoli, M; Bignotti, E; Califano, D; Cecere, SC; Chiodini, P; Citeroni, E; De Angelis, C; De Cecco, L; Del Sesto, M; Forlani, L; Lorusso, D; Mezzanzanica, D; Paolini, B; Perrone, F; Pignata, S; Russo, D; Schettino, C; Scognamiglio, G; Simeon, V; Spina, A; Tognon, G; Tomassetti, A | 1 |
| Barar, J; Erfan-Niya, H; Fathi, M; Omidi, Y | 1 |
| Poursheikhani, A; Seyed H, G; Tavakoli-Bazzaz, J; Yousefi, H | 1 |
| Antony, J; El-Bahrawy, M; Gabra, H; Karali, E; Louis, LS; McKie, AB; Okon, IS; Recchi, C; Stebbing, J; Vaughan, S; Zanini, E | 1 |
| Bown, JL; Deeni, YY; Kankia, IH; Khalil, HS; Langdon, SP; Moult, PR | 1 |
| Bryant, A; Gaitskell, K; Goodall, RJ; Lyons, TJ; Morrison, J; Thoma, C; Wiggans, AJ | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E | 1 |
| Anderson, R; Berns, EM; Boeckx, B; Casado, A; Coens, C; Despierre, E; Ferrero, A; Hirsch, FR; Jimeno, A; Katsaros, D; Lambrechts, D; Ray-Coquard, I; Varella-Garcia, M; Vergote, I | 1 |
| Li, H; Shi, C; Sui, H; Yan, Z | 1 |
| Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E | 1 |
| Abdul, UK; Berndsen, RH; Dyson, PJ; Griffioen, AW; Meraldi, P; Nowak-Sliwinska, P; Weiss, A; Wong, TJ | 1 |
| Balko, JM; Black, EP | 1 |
| Ellard, SL; Fisher, B; Grimshaw, R; Hirte, H; Oza, A; Seymour, L; Swenerton, K; Tsao, M | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Murphy, M; Stordal, B | 1 |
| Akar, U; Bartholomeusz, C; Esteva, FJ; Kazansky, A; Kigawa, J; Kondo, K; Krishnamurthy, S; Lee, J; Liu, P; Oishi, T; Saso, H; Ueno, NT | 1 |
| Gui, T; Shen, K | 1 |
| Bezler, M; Hengstler, JG; Ullrich, A | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Baselga, J; Hammond, LA | 1 |
| Lorusso, PM | 1 |
| Vasey, PA | 1 |
| Pérez-Soler, R | 1 |
| Blank, SV; Chang, R; Muggia, F | 1 |
| Sabbatini, P | 1 |
| Auer, D; Daxenbichler, G; Egle, D; Marth, C; Rössler, J; Vergote, I; Zeimet, AG | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Faoro, L; Fleming, GF; Friberg, G; Kasza, K; Morgan, RJ; Nimeiri, HS; Oza, AM; Salgia, R; Stadler, WM; Vokes, EE | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
8 review(s) available for erlotinib hydrochloride and Cancer of Ovary
| Article | Year |
|---|---|
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Progression-Free Survival; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2018 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
10 trial(s) available for erlotinib hydrochloride and Cancer of Ovary
| Article | Year |
|---|---|
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan | 2014 |
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Mutation; Organoplatinum Compounds; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases | 2015 |
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quinazolines | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A | 2010 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2003 |
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Selection; Peritoneal Neoplasms; Quinazolines; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
17 other study(ies) available for erlotinib hydrochloride and Cancer of Ovary
| Article | Year |
|---|---|
Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer.
Topics: Animals; Asparaginase; Cell Line, Tumor; Drug Delivery Systems; Erlotinib Hydrochloride; Female; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Nanoparticles; Ovarian Neoplasms; Spectroscopy, Fourier Transform Infrared | 2022 |
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
Topics: Bevacizumab; Biomarkers; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mangifera; Ovarian Neoplasms | 2023 |
Methotrexate-conjugated chitosan-grafted pH- and thermo-responsive magnetic nanoparticles for targeted therapy of ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Female; Humans; Magnetite Nanoparticles; Methotrexate; Ovarian Neoplasms | 2020 |
EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Ligands; MAP Kinase Kinase Kinases; Ovarian Neoplasms; Signal Transduction | 2020 |
The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Topics: Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2017 |
NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; MCF-7 Cells; NF-E2-Related Factor 2; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Tetrahydronaphthalenes | 2017 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; BRCA1 Protein; BRCA2 Protein; Cadaverine; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles | 2015 |
Combination of ruthenium(II)-arene complex [Ru(η
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cellular Senescence; Chickens; Chorioallantoic Membrane; Cymenes; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neovascularization, Physiologic; Organometallic Compounds; Ovarian Neoplasms | 2017 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Topics: Adenocarcinoma, Clear Cell; Animals; Apoptosis Regulatory Proteins; Benzimidazoles; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Ovarian Neoplasms; Phosphoproteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Topics: ADAM Proteins; ADAM17 Protein; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Doxorubicin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Ovarian Neoplasms; Ovary; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2012 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; CA-125 Antigen; Cell Growth Processes; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Ovarian Neoplasms; Quinazolines; Radioimmunoassay | 2007 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |